Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?-Reference-Cited by-同舟云学术

Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?

Published:2015-05-27 Issue:7 Volume:24 Page:709-715
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Alqahtani Saad¹,Seoane-Vazquez Enrique¹²,Rodriguez-Monguio Rosa³⁴,Eguale Tewodros¹²⁵

Affiliation:

1. International Center for Pharmaceutical Economics and Policy; Massachusetts College of Pharmacy and Health Sciences (MCPHS University); Boston MA USA

2. Division of General Medicine and Primary Care; Brigham and Women's Hospital; Boston MA USA

3. School of Public Health and Health Sciences; University of Massachusetts; Amherst MA USA

4. The Institute for Global Health; University of Massachusetts; Amherst MA USA

5. Department of Medicine; McGill University; Montreal Quebec Canada

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference41 articles.

1. The challenge of globalization in pharmaceutical law-is an international drug approval system modeled after the European system worth considering?;Purnhagen;Food Drug Law J,2008

2. Comparison of drug approvals in Europe versus the United States: an analysis of discrepancies between drug products reviewed by EMA and FDA;Makuch;Therapeutic Innovation & Regulatory Science,2014

3. Convergence versus social embeddedness;Saltman;European J Public Health,1997

4. Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development;Nieminen;Eur J Pharm Biopharm,2005

5. What is past is prologue: the international conference on harmonization and lessons learned from European drug regulations harmonization;Lee;University of Pennsylvania Journal of International Economic Law,2005

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals;Clinical and Translational Science;2024-07

2. Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market;Health Economics;2024-03-15

3. Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines;BMJ Public Health;2024-02

4. Assessing ISO 18404 standard applicability in the service sector: a qualitative study;The TQM Journal;2024-01-18

5. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations;Therapeutic Innovation & Regulatory Science;2023-10-20